Lynch syndrome is the fourth most common cancer in the United States, with an early age of onset and poor prognosis. Here, we present a unique case of a patient with progressive colon cancer due to a late diagnosis of Lynch syndrome showing excellent response to immunotherapy. A 59-year-old male with a history of rectal cancer 30 years ago came to the hospital due to a fever and further found a large necrotic colon mass. Biopsy was positive for colorectal cancer; however, due to the size of the tumor, the patient was deemed not a surgical candidate and offered hospice with palliative chemotherapy. Based on further workup, the patient was diagnosed with Lynch syndrome, with colon cancer determined to be responsive to Immunotherapy. He was started on JEMPERLI (Dosterlimab-gxly), and after three cycles of therapy, imaging and PET scan were repeated, showing decreased activity and extent of the tumor—a tremendous success.
References
[1]
Sinicrope, F.A. (2018) Lynch Syndrome-Associated Colorectal Cancer. The New England Journal of Medicine, 379, 764-773. https://doi.org/10.1056/NEJMcp1714533
[2]
Bhattacharya, P. and McHugh, T.W. (2023) Lynch Syndrome. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK431096/
Mirza, M.R., Chase, D.M., Slomovitz, B.M., et al. (2023) RUBY Investigators. Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer. The New England Journal of Medicine, 388, 2145-2158. https://doi.org/10.1056/NEJMoa2216334
[6]
Kim, J.Y. and Byeon, J.S. (2019) Genetic Counseling and Surveillance Focused on Lynch Syndrome. Journal of the Anus, Rectum and Colon, 3, 60-68. https://doi.org/10.23922/jarc.2019-002
[7]
Aaltonen, L.A., Salovaara, R., Kristo, P., et al. (1998) Incidence of Hereditary Nonpolyposis Colorectal Cancer and the Feasibility of Molecular Screening for the Disease. The New England Journal of Medicine, 338, 1481-1487. https://doi.org/10.1056/NEJM199805213382101
[8]
Lynch, H.T., Snyder, C.L., Shaw, T.G., et al. (2015) Milestones of Lynch Syndrome: 1895-2015. Nature Reviews Cancer, 15, 181-194. https://doi.org/10.1038/nrc3878
[9]
NCCN Clinical Practice Guidelines in Oncology: Genetic/Familial High-Risk Assessment: Colorectal Version I.2015. Fort Washington, PA: National Comprehensive Cancer Network, 2016.
[10]
Zaanan, A., Shi, Q., Taieb, J., et al. (2018) Role of Deficient DNA Mismatch Repair Status in Patients with Stage III Colon Cancer Treated with FOLFOX Adjuvant Chemotherapy: A Pooled Analysis from 2 Randomized Clinical Trials. JAMA Oncology, 4, 379-383. https://doi.org/10.1001/jamaoncol.2017.2899
[11]
André, T., Berton, D., Curigliano, G., et al. (2023) Antitumor Activity and Safety of Dostarlimab Monotherapy in Patients with Mismatch Repair Deficient Solid Tumors: A Nonrandomized Controlled Trial. JAMA Network Open, 6, e2341165. https://doi.org/10.1001/jamanetworkopen.2023.41165
[12]
Singh, V., Sheikh, A., Abourehab, M.A.S. and Kesharwani, P. (2022) Dostarlimab as a Miracle Drug: Rising Hope against Cancer Treatment. Biosensors(Basel), 12, Article 617. https://doi.org/10.3390/bios12080617
